Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Kawasaki Heavy Industries, Nokia Bell Labs, Franklin Templeton, City National Bank, Artron Ventures Inc. and Kilpatrick Townsend Join EvoNexus Board Directors



Reading Time: 4 minutes

SAN DIEGO–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;#DisruptiveTechnologylt;/agt;–EvoNexus, Southern California’s premier technology incubator, today
announced six industry sector executives were elected to its Board of
Directors; three were elected in Q1 and three on May 10. The new
Directors hail from well-established international organizations
including: Franklin Templeton, one of the world’s largest
asset managers; City National Bank, a subsidiary of Royal Bank of
Canada, one of North America’s leading diversified financial services
companies with offices in Canada, the United States and 33 other
countries; Kawasaki Heavy Industries (USA), a technology
corporate group with about 100 group companies in Japan and overseas
sending diverse products into wide-ranging fields; Nokia Bell Labs,
providing technology, products, services and licensing to connect the
world via 5G and the IoT; Artron Ventures Inc., a subsidiary of
TOA Electric Industrial Co., Ltd. the worldwide electronic parts
distributor; and Kilpatrick Townsend & Stockton LLP
law firm that provides counsel to companies and brands from around the

“We continue to attract accomplished business leaders and their
companies from diverse sectors to EvoNexus,” said Rory
Moore, CEO and Co-Founder of EvoNexus
. “Our new board members bring
varied domain expertise, energy and strategic partnerships to EvoNexus
and our startup portfolio.”

Moore continued, “The convergence of industries and hyper-connectivity
is blurring traditional business boundaries providing opportunities for
new collaboration, innovation and competition. The potential of
technologic applications is widening, which is reflected in our
strategic partnerships, board members and portfolio of disruptive
startups that are expanding into new sectors. Startups typically enter
markets with disruptive innovation. This is occurring within
agriculture, chemicals, healthcare, automotive, consumer electronics,
and industrial equipment to name a few, as well as new technology
acceleration within banking, finance and insurance with a plethora of
emerging FinTech startups.”

About the New Elected EvoNexus Board Directors

Linda Duncombe, Executive Vice President of Marketing and Product
National Bank
, is a member of the company’s Executive
Committee. Prior to joining City National, she was global head of design
for Citibank’s Global Consumer Bank and the chief marketing officer and
head of growth for Citi FinTech. Ms. Duncombe, born in Australia, began
her career with National Australia Bank and later served as the head of
customer franchise with Citi in Australia. She earned her bachelor’s
degree from Western Sydney University. She is a graduate of Harvard
Business School’s Advanced Management Program and completed Citi’s
Women’s Leadership Development Program at the UCLA Anderson School of
Management. Active in community and civic affairs, Ms. Duncombe serves
on the board of the Global Retail Management Association.


Takaki Morihara/Chief Operating Officer, Artron
Ventures Inc.
, is leading the discovery of new technology and
startups. He has more than 15 years of experience in the hardware
industry with multiple responsibilities in sales, marketing and
engineering for several markets including consumer, automotive,
semiconductor and optical communications. Mr. Morihara began his career
as an acoustic engineer for automotive speakers at Foster Electric
managing sales to SONY, Alpine and Samsung. He has previously held new
business development branch manager positions for TOA Electrical
Industrial in both California and Texas.

Richard Christiansen/Partner, Kilpatrick Townsend & Stockton LLP,
a multi-practice international law firm, focuses his practice on patent
prosecution and transactional intellectual property for a broad range of
technologies in software, mechanical and electrical spaces for clients
in all lifecycle stages from multinationals to early startups. Mr.
Christiansen has helped clients receive patents for medical devices, AI,
online security and content delivery, FinTech, clean technology,
electromechanical systems and heavy equipment. Prior to his legal
career, Mr. Christiansen was a design engineer at Raytheon Missile
Systems. He has been involved with many startups and new companies,
including as a founder and mentor. Mr. Christiansen obtained a B.S. in
Mechanical Engineering from Brigham Young University and a J.D. from New
York University School of Law.

Masanori Hamamatsu/Technical Director of Strategic Research
Heavy Industries (USA)
, is responsible for Kawasaki R&D
projects. He is currently working on Research & Technology Scouting,
Business Development and Investment deal scouting of IIoT/AI
applications/Robotics/Mobility/Energy related to Kawasaki current and
future businesses. He started his career at Kawasaki Heavy Industries in
1991. He holds a bachelor’s degree in Control Engineering from Osaka
University, Japan.

Joe Boerio/Senior Vice President and Chief Technology Officer (CTO), Franklin
(FT) [NYSE:BEN], leads Investment Management
Data Science, FinTech and Rapid Development for Franklin Templeton
Investments. As CTO he is responsible for setting and executing the
firm’s strategic technology direction for Investment Management, Data
Science and Cyber Security including FT’s internal FinTech venture. Mr.
Boerio is a strong visionary leader with 30+ years of proven execution
results in enterprise IT, operational excellence and global business
enablement. He is the Chair of the Investment Company Institute
Technology Committee based in Washington, D.C. and serves on the Board
of the FinTech Sandbox in Boston. He earned his bachelor’s degree in
information systems management from the University of San Francisco.

Nitin Shah, PhD/Principal Innovator, Nokia
Bell Labs
, is responsible for leading technology incubation and
commercialization. Based in Silicon Valley, he is an innovator and
inventor with a record of developing technologies and architecture for
mobile networks from concept to commercialization. He has experience
with multi-national corporations, startups and solo consulting in the
mobile communications and digital media industries. His primary focus is
on roadmaps and market disruptions to drive profitable innovation in
mobile networking. Dr. Shah holds a BA and MA in Natural Sciences and a
PhD in Microelectronics from the University of Cambridge in England. He
holds 15 patents in the areas of mobile networks, digital media and
quantum engineering. His past clients/inhouse positions include AT&T,
Lucent Technologies, Ericsson, Nokia and DoCoMo.


About EvoNexus

EvoNexus is Southern California’s leading startup incubator with
locations in San Diego and Irvine. We enable motivated entrepreneurs to
turn their transformative technologies into fundable,
commercially-viable companies. Since 2010, $1.7B in funding and
acquisition outcomes have been achieved by EvoNexus startups. A total of
26 EvoNexus startups have been acquired since 2013. EvoNexus is
supported by strategic corporate sponsors in technology, life science
and leading sector service providers. EvoNexus companies enjoy
incubation of up to two years in Class A offices and dry lab spaces to
create complex products, secure investor funding and launch their
inventions into important markets. For more information, please visit


EvoNexus Press Contact:
Carolyn Holck
[email protected]
(858) 254-0440


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493


Rodedawg (OTC: RWGI) Launches TikTok Shop to Expand into Global E-Commerce Market



Continue Reading


Industrial Hemp Market Soars from $6.6 Billion to $25.7 Billion by 2034, Fueled by Sustainable Innovation




Industrial Hemp Playing Key Role in Carbon Sequestration and Soil Remediation Aligning with Sustainable Farming Practices

ROCKVILLE, Md., June 12, 2024 /PRNewswire/ — Based on a new research report by Fact.MR, worldwide sales of Industrial Hemp Market are estimated to reach US$ 6.6 billion in 2024. By 2034, this market is anticipated to skyrocket to a staggering US$ 25.7 billion, driven by a steady CAGR of 14.5% from 2024 onward.

Demand for industrial hemp is skyrocketing as more and more industries recognize its versatile and sustainable properties. Once overlooked, this remarkable crop is now being embraced for its myriad uses across various sectors. From textiles and construction materials to biofuels and nutritional supplements, hemp’s applications are seemingly endless.

Environmentally conscious consumers are driving much of this demand, as hemp requires minimal pesticides and herbicides, making it an eco-friendly choice for sustainable farming. Its ability to sequester carbon dioxide and remediate contaminated soil further adds to its appeal. Moreover, hemp’s durability, lightweight nature, and renewable qualities make it an attractive alternative to traditional materials in manufacturing.

Request a Sample of this Report:


As awareness of hemp’s benefits continues to spread, industries are investing in research and development to unlock its full potential. With its multi-faceted applications and sustainable credentials, industrial hemp is poised to become a cornerstone of the green economy, meeting the growing demand for environmentally responsible products and practices.

Key Takeaways from the Market Study:

  • Based on nature, sales of organic hemp are estimated to reach a valuation of $3.2 billion in 2024.
  • The market in Mexico is evaluated to expand at a CAGR of 13.6% from 2024 to 2034.
  • Revenue from sales of industrial hemp in East Asia is projected to reach $5.9 billion by the end of 2034.
  • The South Korean market is evaluated to reach a valuation of $1.4 billion by the end of 2034.
  • North America is analyzed to hold a global market share of 24.3% by 2034.

“Use of industrial hemp in textiles, medicines, and food, coupled with global sustainability trends, is creating opportunities for suppliers. Governments worldwide are collaborating to boost global hemp distribution,” says a Fact.MR analyst.

Increasing Awareness of Therapeutic Potential of Hemp in Medical Applications

Once relegated to the fringes, industrial hemp is rapidly emerging as a sustainable wonder crop, fueling a wave of cutting-edge innovations across diverse industries. As researchers and entrepreneurs unlock its vast potential, hemp is proving to be a versatile and eco-friendly resource, paving the way for exciting new products and applications.

The automotive industry is also exploring the use of hemp fibers as a reinforcement material for lighter, stronger, and more sustainable car parts. These natural fiber composites could reduce vehicle weight, improving fuel efficiency and reducing emissions.


In the field of biotechnology, scientists are harnessing the unique properties of hemp to develop innovative products. For instance, researchers are exploring the use of hemp-derived compounds, such as cannabidiol (CBD), for their potential therapeutic applications in various medical conditions.

Japan’s Industrial Hemp Market Poised for Rapid Growth

The industrial hemp market in Japan is projected to grow at a compound annual growth rate (CAGR) of 15.1% from 2024 to 2034, with the country expected to hold a 29.4% market share by the end of the period.

Increased investment in research is crucial for unlocking the full potential of industrial hemp. Research efforts may focus on improving hemp genetics for higher yield and quality, optimizing cultivation practices, and exploring innovative applications such as advanced nanomaterials or pharmaceuticals. This investment fosters innovation and establishes a foundation for the hemp industry’s long-term growth and competitiveness in an ever-evolving market.

Get Customization on this Report for Specific Research Solutions:


Expanding Opportunities in the United States Industrial Hemp Market

The industrial hemp market in the United States offers abundant opportunities for stakeholders to broaden their product portfolios. Beyond traditional uses like textiles and oils, there is significant potential for hemp-based products to evolve into biodegradable polymers, eco-friendly packaging, and even biofuels. This diversification, a prominent trend in the industrial hemp market, not only targets emerging markets but also positions hemp as a versatile and sustainable resource with applications across various industries.

More Valuable Insights on Offer:

Fact.MR, in its new offering, presents an unbiased analysis of the industrial hemp market for 2019 to 2023 and forecast statistics for 2024 to 2034.

The study divulges essential insights into the market based on nature (organic, conventional), product type (fiber, seeds), and end use (food & beverages, consumer textiles, personal products, industrial applications, hemp CBD, supplements, other consumer products), across seven major regions of the world (North America, Latin America, Eastern Europe, Western Europe, East Asia, South Asia & Pacific, and MEA).


Check out More Related Studies Published by Fact.MR Research:

Hemp-Based Products Market is expected to reach $1.8 billion in 2023 and jump to a size of $16.2 billion by 2033.

Cannabis Infused Drinks Market is predicted to race ahead and end up at US$ 8.7 billion by 2032.

Ready-to-use Therapeutic Food Market to surge from $459.9M in 2024 to $800.6M by 2034, driven by 5.7% CAGR, marking substantial growth.

Specialty Fat and Oil Market will hit $85.94 billion by 2034 with a 4.6% Annual Growth Rate.


Baking Ingredient Market is set to reach $41.48 billion by 2034, Driven by 6.5% Annual Growth Rate.

Infant Milk Formula Market: From Growth Spurts to Baby Boom – Projected Surge to $22.35 Billion by 2034.

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape. 


11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team[email protected]
Follow Us: LinkedIn | Twitter | Blog


View original content:–fueled-by-sustainable-innovation-302170602.html

Continue Reading


Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs




HERZLIYA, Israel and CALGARY, AB, June 11, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the success and conclusion of a preliminary safety evaluation of Innocan’s single injection and sustained-release LPT-CBD conducted on minipigs. The animals demonstrated excellent drug tolerance and did not exhibit any drug-related adverse events.



Recognized by the FDA as an excellent model for toxicology, small breeds of miniature domestic pigs known as minipigs share strong similarities with humans in crucial aspects such as drug metabolism, skin structure, genetics, and physiological mechanisms. In this preliminary safety study, minipigs received a single subcutaneous injection of LPT-CBD and were closely monitored for pharmacokinetics and basic safety parameters over one month. Encouragingly, the animals all exhibited good drug tolerance and did not manifest any drug-related adverse reactions.

“We are thrilled with these findings, which further underpin the safety profile of LPT-CBD following a single injection,” commented Dr. Eyal Kalo, the R&D Director of Innocan Pharma. “With each new data point collected for LPT-CBD, we make significant strides in our quest to revolutionize patient care through sustained-release therapy. Our efforts to continuously gather data to fully characterize LPT-CBD are paramount in our journey towards its ultimate approval.”


Professor Chezy Barenholz the CSO of Innocan Pharma added, “These results are immensely gratifying and hold significant promise as they highlight the characteristics of LPT-CBD in a physiological setting similar to humans.”

The study involved administering three ascending doses of LPT-CBD via subcutaneous injection in minipigs, followed by comprehensive monitoring of pharmacokinetics and safety parameters for 28 days. Throughout the study, the minipigs demonstrated excellent drug tolerance, as evidenced by blood clinical parameters whithin normal range, healthy appetite, and normal behavior. These findings are consistent with prior safety evaluations conducted with LPT-CBD on diverse animal models including goats and dogs, affirming the drug’s favorable tolerability profile following both single and repeated use.

Grant of Restricted Share Units                                                                                                 

The Company has granted an aggregate of 290,000 restricted share units (each, an “RSU“) to consultants. Each RSU entitles the recipient to receive one common share of the Company (a “Common Share“) on vesting. A total of 150,000 RSUs vest on May 30, 2024, and 140,000 RSUs vest on September 30, 2024. The RSUs and the underlying Common Shares are subject to a statutory hold period of four months and one day expiring on October 1, 2024.

Innocan also announces that it granted 2,380,000 stock options to employees and consultants to the Company. These options have a strike price of $0.28, with various vesting periods up to 12 months. All options expire on May 30, 2029.


About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales.

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
[email protected] 



Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.



Cision View original content:

Continue Reading

Latest news

Trending on Grassnews Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania